Related Experiment Video
Updated: Aug 31, 2025
Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant
Yongwei Gu1,2, Yue Du1,2,3, Liangdi Jiang1,2,4
1Department of Pharmacy, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Background:
Melanoma is the most malignant skin tumor and is difficult to cure with the alternative treatments of chemotherapy, biotherapy, and immunotherapy. Our previous study showed that triptolide (TP) exhibited powerful tumoricidal activity against melanoma. However, the clinical potential of TP is plagued by its poor aqueous solubility, short half-life, and biotoxicity. Therefore, developing an ideal vehicle to efficiently load TP and achieving targeted delivery to melanoma is a prospective approach for making full use of its antitumor efficacy.
Results:
We applied exosome (Exo) derived from human umbilical cord mesenchymal stromal cells (hUCMSCs) and engineered them exogenously with a cyclic peptide, arginine-glycine-aspartate (cRGD), to encapsulate TP to establish a bionic-targeted drug delivery system (cRGD-Exo/TP), achieving synergism and toxicity reduction. The average size of cRGD-Exo/TP was 157.34 ± 6.21 nm, with a high drug loading of 10.76 ± 1.21%. The in vitro antitumor results showed that the designed Exo delivery platform could be effectively taken up by targeted cells and performed significantly in antiproliferation, anti-invasion, and proapoptotic activities in A375 cells via the caspase cascade and mitochondrial pathways and cell cycle alteration. Furthermore, the biodistribution and pharmacokinetics results demonstrated that cRGD-Exo/TP possessed superior tumor targetability and prolonged the half-life of TP. Notably, cRGD-Exo/TP significantly inhibited tumor growth and extended survival time with negligible systemic toxicity in tumor-bearing mice.
Conclusion:
The results indicated that the functionalized Exo platform provides a promising strategy for targeted therapy of malignant melanoma.
Insights
Engineered exosomes loaded with triptolide (TP) show potent melanoma treatment. This targeted drug delivery system (cRGD-Exo/TP) enhances efficacy and reduces toxicity, offering a promising melanoma therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Melanoma is a highly malignant skin cancer with limited treatment options.
- Triptolide (TP) shows potent anti-melanoma activity but suffers from poor solubility, short half-life, and toxicity.
- Targeted drug delivery systems are needed to improve TP's therapeutic potential.
Purpose of the Study:
- To develop a bionic-targeted drug delivery system for triptolide (TP) using engineered exosomes.
- To evaluate the efficacy and safety of the cRGD-Exo/TP system for melanoma treatment.
Main Methods:
- Human umbilical cord mesenchymal stromal cell-derived exosomes (hUCMSCs-Exo) were engineered with cyclic arginine-glycine-aspartate (cRGD) peptide.
- Triptolide (TP) was encapsulated into cRGD-engineered exosomes to form cRGD-Exo/TP.
- In vitro studies assessed A375 melanoma cell uptake, antiproliferation, anti-invasion, apoptosis, and cell cycle effects.
- In vivo studies evaluated biodistribution, pharmacokinetics, tumor growth inhibition, and survival in tumor-bearing mice.
Main Results:
- The cRGD-Exo/TP system exhibited a size of 157.34 nm and high drug loading (10.76%).
- In vitro, cRGD-Exo/TP demonstrated effective cellular uptake and significant antiproliferative, anti-invasive, and proapoptotic effects in A375 cells.
- In vivo, cRGD-Exo/TP showed enhanced tumor targeting, prolonged TP half-life, significant tumor growth inhibition, extended survival, and minimal systemic toxicity.
Conclusions:
- Functionalized exosomes serve as an effective platform for targeted melanoma therapy.
- The cRGD-Exo/TP system offers a promising strategy to overcome TP's limitations and improve melanoma treatment outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy